Viveve Inc View News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Topline results of the 12-month primary efficacy endpoint anticipated in January 2023Positive results may support a de novo marketing application for a new U.S. indication for treatment of stress urinary

United statesScott durbinBill berryViveve inc viewInternational consultation on incontinence modular questionnaireDrug administrationViveve incViveve medical incBerry company public relationsSecurities exchangeViveve medicalPad weight testSocial aspectsIncontinence qualityPatient global impressionInternational consultation